Jazz Pharmaceuticals PLC (JAZZ)

142.60 +1.95  +1.39% NASDAQ Nov 21, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/26/2020 16:30 EST Misc Jazz Pharmaceuticals PLC Fourth Quarter Earnings Conference Call in 2019
02/26/2020 Earnings Jazz Pharmaceuticals PLC Fourth Quarter Earnings in 2019 Release
11/05/2019 16:30 EST Misc Jazz Pharmaceuticals PLC Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Jazz Pharmaceuticals PLC Third Quarter Earnings in 2019 Release
08/06/2019 16:30 EDT Misc Jazz Pharmaceuticals PLC Second Quarter Earnings Conference Call for 2019
08/06/2019 Earnings Jazz Pharmaceuticals PLC Second Quarter Earnings Results for 2019
08/01/2019 Misc Jazz Pharmaceuticals PLC Annual General Meeting in 2018
05/07/2019 16:30 EDT Misc Jazz Pharmaceuticals PLC First Quarter Earnings Conference Call in 2019
05/07/2019 Earnings Jazz Pharmaceuticals PLC First Quarter Earnings in 2019 Release
02/26/2019 16:30 EST Misc Jazz Pharmaceuticals PLC Fourth Quarter Earnings Conference Call in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.jazzpharmaceuticals.com
  • Investor Relations URL: http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: Feb. 26, 2020
  • Last Earnings Release: Nov. 05, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, as well as Erwinaze for acute lymphoblastic leukemia, Defitelio for severe veno-occlusive disease after stem cell transplant, and Vyxeos for acute myeloid leukemia.

Top Fund Holders

Symbol Name Weighting
PVSMX Putnam Capital Spectrum M 13.16%
PYSMX Putnam Equity Spectrum M 13.00%
XPH SPDR® S&P Pharmaceuticals ETF 4.54%
IHE iShares US Pharmaceuticals ETF 3.28%
PPH VanEck Vectors Pharmaceutical ETF 3.00%
PJP Invesco Dynamic Pharmaceuticals ETF 2.76%
FRBRX Franklin Biotechnology Discovery R6 2.44%
FXH First Trust Health Care AlphaDEX® ETF 2.21%
RBF1092 RBC U.S. Mid-Cap Value Equity Fund D 2.16%
DMCYX BNY Mellon Opportunistic Midcap Value Y 2.13%
FZAKX Fidelity Advisor® Leveraged Co Stk Z 1.94%
IBB iShares Nasdaq Biotechnology ETF 1.03%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.